The start of something
Developments in areas such as 3D printing and sensor technology are ushering in a new era of MRI design, with two current projects highlighting the growing potential for wearable MRI devices. Paul Miller hears from research teams at NYU School of Medicine, the University of Nottingham and University College London who are leading the charge.
The future of the discipline
Artificial intelligence is rapidly moving from an experimental phase to implementation in many fields, including medicine. It is anticipated that the use of AI in the field over the next decade will significantly improve the quality, value and depth of radiology’s contribution to patient care and population health, as well as revolutionise radiologists’ workflows. Here, the Canadian Association of Radiologists ask how best we can handle the transition to new working practices and standards.
An air of distinction
Nanoscientists at Rice University have demonstrated a method for loading iron inside nanoparticles to create MRI contrast agents that outperform gadolinium chelates, the mainstay contrast agent that is facing increased scrutiny due to safety concerns. James Sanderson hears from members of the project team on the impact this discovery could have on future diagnoses and treatments.
Bit by bit
In ongoing efforts to reduce radiation exposure to patients and healthcare professionals alike, how big a role might a new generation of radiation dose monitoring software have to play? The UK’s National Institute for Health and Care Excellence (NICE) has developed a Medtech innovation briefing, inviting input from industry specialists on existing and incoming measurement techniques.
A ray of hope
In a significant development for the use of X-rays in cancer treatment, a group of Australian scientists have engineered ‘X-ray-triggerable liposomes’. These tiny bubbles, filled with chemotherapy drugs, are injected into the body and release their payload when activated by an X-ray. Tim Gunn takes a look at this procedure, which combines two cancer treatments with immense precision and has the potential to be more effective at lower doses than either could be on its own.